中性
官方
反垄断医疗健康知识产权
FTC提交法庭之友简报保护生物药市场竞争
来源：FTC · 发布：2026-08-21
美国联邦贸易委员会（FTC）在反垄断诉讼中提交法庭之友简报，指控制药商安进（Amgen）通过操控专利申请，非法获取恩贝舒（Enbrel）药物的独家专利权，从而延长其对生物药市场的垄断。该药物用于治疗类风湿性关节炎等炎症性疾病。
The FTC filed an amicus brief in an antitrust case, alleging that Amgen illegally secured exclusive patent rights over Enbrel—a biologic drug for rheumatoid arthritis—by shaping patent applications, thereby extending its market monopoly.
为何重要：
此案关乎生物药市场公平竞争，若允许企业通过专利策略规避仿制药进入，将阻碍可及性并损害患者利益，影响整个生物医药行业创新与监管平衡。
This case impacts fair competition in biologics markets; allowing patent evergreening undermines access and patient affordability, affecting innovation and regulatory integrity across the pharmaceutical industry.
本页内容由 AI 自动整理自公开来源，仅供信息参考，不构成法律意见。版权归原作者/原机构所有。
Content on this page is AI-curated from public sources for information only — not legal advice. Copyright belongs to the original authors/organizations.
© 2026 PDFnoted (pdfnoted.com) · 返回行业洞察